Analyst Tyler Van Buren from TD Cowen maintained a Buy rating on Arcutis Biotherapeutics and increased the price target to $25.00 from $20.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tyler Van Buren has given his Buy rating due to a combination of factors that highlight Arcutis Biotherapeutics’ strong performance and growth potential. The company’s total product sales have exceeded expectations, with a notable increase in prescription growth and stable gross-to-net (GTN) ratios. This indicates effective commercial execution and a promising outlook for near-term growth driven by expanding indications and strategic market dynamics.
Furthermore, the Zoryve portfolio’s coverage by major pharmacy benefit managers and significant insurance coverage supports its market penetration. The company’s strategic initiatives, such as the launch of a dedicated pharmacy and expansion into new patient demographics, are expected to bolster mid-term growth. Additionally, the potential for long-term growth is supported by the company’s pipeline and life-cycle management strategies, making Arcutis Biotherapeutics a compelling investment opportunity.
Van Buren covers the Healthcare sector, focusing on stocks such as Regeneron, Soleno Therapeutics, and Moderna. According to TipRanks, Van Buren has an average return of -1.5% and a 43.15% success rate on recommended stocks.